Developer docs
API playgroundTry for free, no card

Search company profiles

Siolta Therapeutics

Full company profile

uuid0000ejw

Namestring
Siolta Therapeutics
Legal namestring
Siolta Therapeutics
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Siolta Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Carlos, California, that develops live biotherapeutic products (LBPs) targeting the microbiome to prevent and treat inflammatory diseases. Its lead program, STMC-103H, is a mixed-strain bacterial consortium in Phase 2 development for prevention of atopic dermatitis, food allergy, and allergic asthma in at-risk infants, having received FDA Fast Track Designation and reported a 64% reduction in atopic dermatitis risk in the ADORED study in November 2025. Two additional programs are in preclinical development: STMC-105 for recurrent bacterial vaginosis and STMC-106 for prevention of necrotizing enterocolitis in preterm infants.

The company's discovery and manufacturing engine is its proprietary Precision Symbiotics Platform, which integrates machine learning, network analysis, high-resolution clinical microbiome data, anaerobic microbiology, and in-house GMP manufacturing to rationally design mixed-species consortia. This platform is supported by a proprietary human microbiota biobank, a portfolio of 9 issued and 29 pending patents, and ongoing NIH SBIR-funded manufacturing innovation. Siolta has assembled an advisory team that includes former FDA Chief Counsel Peter Hutt, Harvard Medical School allergy KOL Joshua Boyce, and the late Gilead Chairman John Martin, alongside founders Susan Lynch (UCSF) and CEO Nikole Kimes.

Siolta is currently pre-revenue and plans to commercialize through traditional pharmaceutical channels (hospital and specialty pharmacies, healthcare provider offices) upon regulatory approval. To date the company has raised approximately $42 million in disclosed equity funding across a $30M Series B (September 2020, led by Khosla Ventures) and a $12M Series C (March 2024), supplemented by multiple NIH SBIR awards and a Bill & Melinda Gates Foundation grant. The company operates with 1-10 employees inside MBC Bio Labs in San Carlos.

Short descriptiontext

Siolta Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products using its Precision Symbiotics Platform to prevent and treat inflammatory diseases, with lead program STMC-103H in Phase 2 trials for allergic disease prevention in at-risk infants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live biotherapeutic products, microbiome therapeutics, clinical-stage biopharmaceuticals, maternal-infant health, inflammatory disease prevention
Industry2 codes
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Microbiome-based Live Biotherapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Live Biotherapeutic Products
TypeOne Time License
Description

Pre-revenue clinical-stage company developing live biotherapeutic products for prevention and treatment of diseases including atopic diseases, bacterial vaginosis, and necrotizing enterocolitis. Revenue will be generated from product sales upon regulatory approval.

sioltatherapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Siolta Therapeutics develops rationally designed, mixed-strain live biotherapeutic products (LBPs) that target the metabolic and immunological roots of inflammatory and allergic diseases rather than their symptoms. Using its proprietary Precision Symbiotics Platform and in-house cGMP manufacturing, the company advances candidates such as STMC-103H (lead, Phase 2 for atopic disease prevention), STMC-105 (recurrent bacterial vaginosis), and STMC-106 (necrotizing enterocolitis) through FDA-approved clinical pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 64% reduction in atopic dermatitis risk among infants who completed a year of treatment
+3 more records
Product overview1 text field

Siolta Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of live biotherapeutic products (LBPs) using its proprietary Precision Symbiotics Platform™. The platform integrates machine learning, bioinformatics, anaerobic microbiology, and in-house GMP manufacturing capabilities to develop mixed-strain bacterial consortia. The company's lead product STMC-103H is in Phase 2 clinical trials for allergic disease prevention, while STMC-105 targets recurrent bacterial vaginosis and STMC-106 targets necrotizing enterocolitis in preterm infants, both in preclinical stages.

Product and service3 records
1STMC-103H
CategoryLive Biotherapeutic Product (Allergic Disease Prevention)
Description

A live biotherapeutic containing a carefully selected mix of beneficial bacteria designed to correct pro-allergic immune development in infants. Currently in Phase 2 clinical trials for the prevention of atopic dermatitis, food allergy, and allergic asthma, with FDA Fast Track Designation and a demonstrated 64% reduction in atopic dermatitis risk in the Phase 2 ADORED study.

2STMC-105
CategoryLive Biotherapeutic Product (Recurrent Bacterial Vaginosis)
Description

A vaginal bacterial consortium live biotherapeutic designed to provide resilience from vaginal microbiota disruption, opportunistic pathogen colonization, and recurrence of bacterial vaginosis. Currently in preclinical development for women of reproductive age.

3STMC-106
CategoryLive Biotherapeutic Product (Necrotizing Enterocolitis Prevention)
Description

A mixed-strain live biotherapeutic designed to colonize the preterm infant gut with protective, infant-derived bacteria to reduce pathogen colonization, reinforce epithelial development, and reduce inflammation for prevention of necrotizing enterocolitis (NEC). Currently in preclinical development.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Cowellnex
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-29
Description

Entered into a joint research agreement in January 2025 to collaborate on microbiome therapeutic development.

sioltatherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Collaboration agreement signed in September 2024 to address necrotizing enterocolitis using combined expertise in microbiome-based therapeutics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Siolta Therapeutics

Microbiome-based Live Biotherapeuticssioltatherapeutics.com

Siolta Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products using its Precision Symbiotics Platform to prevent and treat inflammatory diseases, with lead program STMC-103H in Phase 2 trials for allergic disease prevention in at-risk infants.

What Siolta Therapeutics does

Siolta Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Carlos, California, that develops live biotherapeutic products (LBPs) targeting the microbiome to prevent and treat inflammatory diseases. Its lead program, STMC-103H, is a mixed-strain bacterial consortium in Phase 2 development for prevention of atopic dermatitis, food allergy, and allergic asthma in at-risk infants, having received FDA Fast Track Designation and reported a 64% reduction in atopic dermatitis risk in the ADORED study in November 2025. Two additional programs are in preclinical development: STMC-105 for recurrent bacterial vaginosis and STMC-106 for prevention of necrotizing enterocolitis in preterm infants.

The company's discovery and manufacturing engine is its proprietary Precision Symbiotics Platform, which integrates machine learning, network analysis, high-resolution clinical microbiome data, anaerobic microbiology, and in-house GMP manufacturing to rationally design mixed-species consortia. This platform is supported by a proprietary human microbiota biobank, a portfolio of 9 issued and 29 pending patents, and ongoing NIH SBIR-funded manufacturing innovation. Siolta has assembled an advisory team that includes former FDA Chief Counsel Peter Hutt, Harvard Medical School allergy KOL Joshua Boyce, and the late Gilead Chairman John Martin, alongside founders Susan Lynch (UCSF) and CEO Nikole Kimes.

Siolta is currently pre-revenue and plans to commercialize through traditional pharmaceutical channels (hospital and specialty pharmacies, healthcare provider offices) upon regulatory approval. To date the company has raised approximately $42 million in disclosed equity funding across a $30M Series B (September 2020, led by Khosla Ventures) and a $12M Series C (March 2024), supplemented by multiple NIH SBIR awards and a Bill & Melinda Gates Foundation grant. The company operates with 1-10 employees inside MBC Bio Labs in San Carlos.

Siolta Therapeutics firmographics

Firmographics
Name
Siolta Therapeutics
Legal name
Siolta Therapeutics
Website
https://sioltatherapeutics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Siolta Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products using its Precision Symbiotics Platform to prevent and treat inflammatory diseases, with lead program STMC-103H in Phase 2 trials for allergic disease prevention in at-risk infants.
Ownership category
akta.pro rank

Siolta Therapeutics industry classification

Industry
Product category
Microbiome-based Live Biotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)

Keywords

  • Live biotherapeutic products
  • Microbiome therapeutics
  • Clinical-stage biopharmaceuticals
  • Maternal-infant health
  • Inflammatory disease prevention

Where Siolta Therapeutics is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Siolta Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Live Biotherapeutic Products: Pre-revenue clinical-stage company developing live biotherapeutic products for prevention and treatment of diseases including atopic diseases, bacterial vaginosis, and necrotizing enterocolitis. Revenue will be generated from product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Siolta Therapeutics product offering

Product offering

Core offering

Siolta Therapeutics develops rationally designed, mixed-strain live biotherapeutic products (LBPs) that target the metabolic and immunological roots of inflammatory and allergic diseases rather than their symptoms. Using its proprietary Precision Symbiotics Platform and in-house cGMP manufacturing, the company advances candidates such as STMC-103H (lead, Phase 2 for atopic disease prevention), STMC-105 (recurrent bacterial vaginosis), and STMC-106 (necrotizing enterocolitis) through FDA-approved clinical pathways.

Product overview

Siolta Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of live biotherapeutic products (LBPs) using its proprietary Precision Symbiotics Platform™. The platform integrates machine learning, bioinformatics, anaerobic microbiology, and in-house GMP manufacturing capabilities to develop mixed-strain bacterial consortia. The company's lead product STMC-103H is in Phase 2 clinical trials for allergic disease prevention, while STMC-105 targets recurrent bacterial vaginosis and STMC-106 targets necrotizing enterocolitis in preterm infants, both in preclinical stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • STMC-103H A live biotherapeutic containing a carefully selected mix of beneficial bacteria designed to correct pro-allergic immune development in infants. Currently in Phase 2 clinical trials for the prevention of atopic dermatitis, food allergy, and allergic asthma, with FDA Fast Track Designation and a demonstrated 64% reduction in atopic dermatitis risk in the Phase 2 ADORED study.
  • STMC-105 A vaginal bacterial consortium live biotherapeutic designed to provide resilience from vaginal microbiota disruption, opportunistic pathogen colonization, and recurrence of bacterial vaginosis. Currently in preclinical development for women of reproductive age.
  • STMC-106 A mixed-strain live biotherapeutic designed to colonize the preterm infant gut with protective, infant-derived bacteria to reduce pathogen colonization, reinforce epithelial development, and reduce inflammation for prevention of necrotizing enterocolitis (NEC). Currently in preclinical development.

Quantifiable outcome

  • 64% reduction in atopic dermatitis risk among infants who completed a year of treatment
  • +3 more outcomes

Companies that use Siolta Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Siolta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Siolta Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CowellnexcoreStrategic or Co-development Partner · 29 January 2025Entered into a joint research agreement in January 2025 to collaborate on microbiome therapeutic development.
  • NexilicocoreStrategic or Co-development Partner · 17 September 2024Collaboration agreement signed in September 2024 to address necrotizing enterocolitis using combined expertise in microbiome-based therapeutics.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Siolta Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Siolta Therapeutics social profiles

Digital presence

Siolta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Siolta Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Siolta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Siolta Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Siolta Therapeutics

What does Siolta Therapeutics do?

Siolta Therapeutics develops rationally designed, mixed-strain live biotherapeutic products (LBPs) that target the metabolic and immunological roots of inflammatory and allergic diseases rather than their symptoms. Using its proprietary Precision Symbiotics Platform and in-house cGMP manufacturing, the company advances candidates such as STMC-103H (lead, Phase 2 for atopic disease prevention), STMC-105 (recurrent bacterial vaginosis), and STMC-106 (necrotizing enterocolitis) through FDA-approved clinical pathways.

Is Siolta Therapeutics a public or private company?

Siolta Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Siolta Therapeutics founded?

Siolta Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Siolta Therapeutics based?

Siolta Therapeutics is headquartered in San Carlos, United States, in the North America region.

How does Siolta Therapeutics make money?

One revenue line is on record: live Biotherapeutic Products.

Does Siolta Therapeutics have an API?

No public API is recorded for Siolta Therapeutics.

What industry is Siolta Therapeutics in?

Siolta Therapeutics's product category is Microbiome-based Live Biotherapeutics. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNecrotizing Enterocolitis Market to Register Stunning Growth at a CAGR of 26% During the Forecast Period (2026–2036) | DelveInsightThe necrotizing enterocolitis market is projected to grow at a 26% CAGR during 2026–2036, driven by increasing preterm birth rates and rising awareness of early diagnosis. Key companies including Infant Bacterial Therapeutics, Siolta Therapeutics, Noveome Biotherapeutics, and Plakous Therapeutics are advancing pipeline candidates such as IBP-9414, STMC-106, ST266, and Protego-PD, with several recent clinical developments including DSMB review completions and Phase III trial publications. The US accounts for the largest market share among the 7MM (US, EU4, UK, Japan), with the market size at USD 30 million in 2025 and no approved drug therapies currently available.PR NewswireSiolta Therapeutics Announces Upcoming Late Breaking Oral Presentation of Results from the Phase 2 ADORED trial at 2026 AAAAI meetingSiolta Therapeutics announced that its abstract presenting one-year results from the Phase 2 ADORED clinical trial of STMC-103H in infants at-risk for atopic diseases has been accepted as a late-breaking oral presentation at the 2026 AAAAI annual meeting. The presentation will take place on February 28, 2026 in Philadelphia, with the abstract to be published in an online supplement to the Journal of Allergy and Clinical Immunology on February 10, 2026. The company's lead live biotherapeutic candidate targets the maternal-infant axis for immune-mediated diseases including atopic dermatitis, food allergy, allergic asthma, and allergic rhinitis.PR NewswireSiolta Therapeutics Reports Positive Phase 2 Results from the ADORED StudySiolta Therapeutics announced positive Phase 2 results from the ADORED study demonstrating that STMC-103H reduced the risk of atopic dermatitis and food allergy in at-risk infants. The trial involved 238 infants across the US and Australia, showing significant efficacy in reducing the development of atopic diseases.nutraingredients.comKirin’s subsidiary and California firm to develop probiotics for suppressing NECCowellnex Inc., a subsidiary of Kirin Holdings, and Siolta Therapeutics have signed an agreement to conduct preclinical joint research on developing probiotics to suppress necrotizing enterocolitis (NEC). The collaboration aims to utilize Siolta’s microbiome science platform to create live bacterial formulations for treating this serious condition in premature infants. This partnership builds on existing scientific evidence linking gut microbiome imbalances and specific prebiotics to the onset of NEC.Business Wire BlogNexilico and Siolta Therapeutics Enter Collaboration Agreement to Develop a Novel Microbiome Therapeutic for Necrotizing EnterocolitisNexilico and Siolta Therapeutics entered a collaboration agreement to develop a multistrain live biotherapeutic product for necrotizing enterocolitis in preterm infants. The partnership combines Nexilico's AI-driven microbiome discovery platform with Siolta's live biotherapeutic development expertise. The collaboration aims to address the underlying causes of NEC development.FinSMEsSiolta Therapeutics Raises $12M in Series C FundingSiolta Therapeutics raised $12M in Series C funding led by SymBiosis and Khosla Ventures. The company will use the funds for clinical development of its lead product STMC-103H and a collaboration with Johns Hopkins University. The lead program is in phase 2 for atopic diseases.VC News DailySiolta Therapeutics Scoops Up $12M Series CSiolta Therapeutics has completed a $12 million Series C financing round, co-led by SymBiosis and Khosla Ventures, with participation from existing investors. This funding round highlights interest in Siolta's microbiome-based therapeutic approach and its progression in developing treatments for various diseases, including atopic diseases and bacterial infections.Pulse 2.0Siolta Therapeutics: $12 Million Raised To Develop Defined-Consortia Live Biotherapeutic ProductsClinical-stage biotech company Siolta Therapeutics completed a $12 million Series C funding round co-led by SymBiosis and Khosla Ventures. The capital will support the clinical development of its lead product STMC-103H, a live biotherapeutic for preventing atopic diseases in newborns, as well as a collaboration with Johns Hopkins University.PR NewswireAllergy Diagnostics Market Size to Reach USD 12.45 Billion in 2030 | Emergen ResearchEmergen Research projects the global allergy diagnostics market will grow from USD 4.80 billion in 2021 to USD 12.45 billion by 2030, representing a CAGR of 11.1%. Market growth is being driven by increasing allergy prevalence (affecting 1.1-10.8% of the global population), rising healthcare investments, and technological innovations including mobile health applications and new antibody testing platforms. Recent funding activity includes Nectar's USD 16.5 million Series A round, Kenota Health's USD 11 million raise, and Reacta's USD 3.5 million fundraising, while partnerships such as LifeMD's collaboration with Allergenis and Bio-Me's agreement with Siolta Therapeutics are expanding market capabilities.openPR.comGlobal Microbiome Cosmetics Market | Key Players are GALLINEE, MATRISYS BIOSCIENCE, Glowbiotics, Inc., Quorum Innovations, Siolta Therapeutics, Revlon, The Estee Lauder Companies Inc., and Yakult HonsThe global microbiome cosmetics market is projected to grow at a CAGR of 29.15% during the forecast period. Asia Pacific is expected to lead global consumption, with China, India, and South Korea as key revenue-generating countries. The market is driven by rising demand for probiotic skincare and technological advancements.